A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Subjects With Stage III/IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms VITAL
- Sponsors Gradalis
- 05 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Sep 2019.
- 07 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
- 21 May 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.